1. Home
  2. ACRE vs TRDA Comparison

ACRE vs TRDA Comparison

Compare ACRE & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ares Commercial Real Estate Corporation

ACRE

Ares Commercial Real Estate Corporation

HOLD

Current Price

$4.66

Market Cap

261.9M

Sector

Real Estate

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$6.95

Market Cap

268.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACRE
TRDA
Founded
2011
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
261.9M
268.6M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
ACRE
TRDA
Price
$4.66
$6.95
Analyst Decision
Hold
Strong Buy
Analyst Count
4
3
Target Price
$5.38
$21.00
AVG Volume (30 Days)
471.2K
299.4K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
11.58%
N/A
EPS Growth
26.17
N/A
EPS
1.35
N/A
Revenue
$54,833,000.00
$25,421,000.00
Revenue This Year
N/A
$39.97
Revenue Next Year
$16.28
$50.80
P/E Ratio
$3.43
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.14
$5.02
52 Week High
$5.89
$16.45

Technical Indicators

Market Signals
Indicator
ACRE
TRDA
Relative Strength Index (RSI) 51.17 49.66
Support Level $4.60 $5.71
Resistance Level $4.69 $7.95
Average True Range (ATR) 0.10 0.41
MACD -0.01 -0.03
Stochastic Oscillator 42.40 37.37

Price Performance

Historical Comparison
ACRE
TRDA

About ACRE Ares Commercial Real Estate Corporation

Ares Commercial Real Estate Corp is a specialty finance company and a real estate investment trust mainly engaged in originating and investing in commercial real estate (CRE) loans and related investments. It operates in one segment, namely originating and managing a diversified portfolio of CRE debt-related investments. The company recognizes the majority of its revenues in the form of interest income, which it receives from loans.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: